Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 March 2025 | Story Litha Banjatwa | Photo Supplied
Fiesta winners 2025
Ons wag vir Godot shines at the 2025 kykNET Fiësta Awards, winning three major accolades and cementing UFS’s reputation for world-class theatre excellence.

Ons wag vir Godot, a groundbreaking stage production from the University of the Free State (UFS) Department of Drama and Theatre Arts, was one of the biggest winners at the 2025 kykNET Fiësta Awards, which celebrate the best of Afrikaans theatre.

The awards ceremony was held at the Kirstenbosch National Botanical Garden in Cape Town on 27 February 2025.

Ons wag vir Godot, an Afrikaans translation of Irish writer Samuel Beckett’s celebrated 1953 play Waiting for Godot, won three of its four nominations: Best Director for Dion van Niekerk, Best Translation for Naomi Morgan, and Best Supporting Actor for Gerben Kamper. This haul positioned Ons wag vir Godot as the second biggest winner of the evening, and marked an unprecedented achievement for a Free State production at the Fiësta Awards.

This success builds upon the play’s earlier triumphs at the Free State Arts Festival, where it received accolades for Best Director, Best Translation, Best Supporting Actor (Peter Taljaard), and Best Ensemble.

Director Dion van Niekerk said what set Ons wag vir Godot apart was its unique origin: it is the first Afrikaans translation of Beckett's masterpiece directly from the French original. Securing the translation rights was no small feat, requiring a special appeal to the notoriously selective Samuel Beckett Estate.

“The production’s greatest challenge lay in making the play accessible to a South African audience,” Van Niekerk said. “We aimed to find a stage language with visual imagery that would situate the play within a recognisable South African context."

This was achieved through Naomi Morgan’s “immaculate translation work, which captured the existential concerns of the play with precisely the right Afrikaans vocabulary and turns of phrase”. The production team further grounded the play in South African reality through the creation of characters, setting, and costuming that evoked the stark beauty of the Karoo landscape.

The success of Ons wag vir Godot has profound implications for the UFS Department of Drama and Theatre Arts. It firmly establishes the department among the nation’s leading drama institutions, showcasing its ability to contribute high-quality, meaningful work to the South African artistic landscape. “This production highlights the importance of performing translated classics,” Van Niekerk said. “Works like Waiting for Godot are part of the canon of great international theatrical works. South Africa was banned from producing this play during apartheid, and it has been rarely seen since, predominantly in English.” This production, therefore, offers Afrikaans-speaking South Africans and others a unique opportunity to engage with Beckett’s timeless work.

The impact of this success extends to the department’s students. Sibabalwe Jokani, a student cast member, shared in the nominations for Best Ensemble at both the Free State Festival and Fiësta Awards. Jokani said the play’s success has inspired the student body and reaffirmed the department’s commitment to high standards and industry access.

When asked about the future of Afrikaans theatre, Van Niekerk said, “This production will hopefully inspire others to continue to reconsider the value that great theatrical works that have been created in other languages might have in a contemporary Afrikaans context.”

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept